Emerging biologics in severe asthma
Príomhchruthaitheoirí: | Pavord, I, Hilvering, B, Shrimanker, R |
---|---|
Formáid: | Journal article |
Foilsithe / Cruthaithe: |
Elsevier
2016
|
Míreanna comhchosúla
-
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
de réir: Shrimanker, R, et al.
Foilsithe / Cruthaithe: (2017) -
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
de réir: Xue, L, et al.
Foilsithe / Cruthaithe: (2015) -
Management and mechanisms of severe eosinophilic asthma
de réir: Shrimanker, R
Foilsithe / Cruthaithe: (2020) -
Exacerbations of severe asthma in patients treated with mepolizumab
de réir: Shrimanker, R, et al.
Foilsithe / Cruthaithe: (2018) -
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
de réir: Howell, I, et al.
Foilsithe / Cruthaithe: (2024)